BackgroundCheck.run
Search For

Thomas J Barta, 61868 March St, Lake Zurich, IL 60047

Thomas Barta Phones & Addresses

Lake Zurich, IL   

Gages Lake, IL   

Gurnee, IL   

Des Plaines, IL   

Lake Zurich, IL   

Lane, IL   

Elk Grove Village, IL   

Madison, WI   

Mentions for Thomas J Barta

Career records & work history

Medicine Doctors

Thomas Barta Photo 1

Thomas Burton Barta

Specialties:
Radiology
Body Imaging
Diagnostic Radiology
Education:
UMDNJ Robert Wood Johnson (1992)

Thomas Barta resumes & CV records

Resumes

Thomas Barta Photo 21

Staff Accountant

Location:
Mchenry, IL
Industry:
Business Supplies And Equipment
Work:
Uline
Staff Accountant
Uline Mar 2018 - Feb 2019
International Financial Analyst
Uline Sep 2016 - Mar 2018
Intercompany Accountant
Uline May 2015 - Aug 2016
Accounts Receivable Clerk
Dick's Sporting Goods Nov 2013 - Apr 2015
Lodge Lead and Key Holder
Education:
Robert Morris University - Illinois 2012 - 2015
Bachelor of Applied Science, Bachelors, Accounting, Finance
Skills:
Inventory Control, Customer Service, Public Speaking, Oracle Applications, Microsoft Excel
Thomas Barta Photo 22

Thomas Barta

Publications & IP owners

Us Patents

4,5-Substituted Imidazolyl Compounds For The Treatment Of Inflammation

US Patent:
6426360, Jul 30, 2002
Filed:
May 15, 2000
Appl. No.:
09/571033
Inventors:
Richard M Weier - Lake Bluff IL
Paul W Collins - Deerfield IL
Michael A Stealey - Libertyville IL
Thomas E Barta - Evanston IL
Renee M Huff - Park Ridge IL
Assignee:
G D Searle Co. - Chicago IL
International Classification:
A01N 4350
US Classification:
514396, 514398, 548254, 5483117, 5483421, 5483335, 5483345, 5483371, 5483381, 5483411, 5483425, 5483255, 5483251, 5483451, 5483435, 5483431
Abstract:
A class of compounds is described for treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula wherein R is selected from lower alkyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxyalkyl, lower alkenyloxyalkyl, mercapto, lower alkylcarbonyl, lower haloalkylcarbonyl, phenylcarbonyl, lower aralkylcarbonyl, lower aralkenyl, lower aryloxyalkyl, lower aralkyloxyalkyl, lower arylsulfonyl, lower aralkylsulfonyl, lower arylthioalkyl, lower heteroarylalkylthioalkyl, and heteroaryl selected from 2-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 4-pyridyl and 2-benzofuryl; wherein R and R are independently selected from heteroaryl, cycloalkyl and aryl, wherein the heteroaryl, cycloalkyl and aryl radicals are substituted at a substitutable position with one or more radicals selected from hydrido, halo, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, aminosulfonyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino and nitro; and wherein R is selected from hydrido, lower alkyl and acyl; or a pharmaceutically-acceptable salt thereof.

N-Hydroxy 4-Sulfonyl Butanamide Compounds

US Patent:
6476027, Nov 5, 2002
Filed:
Dec 6, 1999
Appl. No.:
09/254531
Inventors:
Clara I. Villamil - Glenview IL
John N. Freskos - Clayton MO
Brent V. Mischke - Defiance MO
Patrick B. Mullins - St. Louis MO
Robert M. Heintz - Ballwin MO
Daniel P. Getman - Chesterfield MO
Joseph J. McDonald - Ballwin MO
Gary A. DeCrescenzo - St. Charles MO
Thomas E. Barta - Evanston IL
Daniel P. Becker - Glenview IL
Assignee:
Monsanto Company - St. Louis MO
International Classification:
A61K 3116
US Classification:
5142378, 514330, 514331, 514357, 514428, 514486, 514575, 544159, 546225, 546226, 546233, 546340, 548568, 560 13, 562621, 562623
Abstract:
An N-hydroxy sulfonyl butanamide compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated N-hydroxy sulfonyl butanamide compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.

Aromatic Sulfone Hydroxamic Acid Metalloprotease Inhibitor

US Patent:
6541489, Apr 1, 2003
Filed:
Jul 31, 2000
Appl. No.:
09/554082
Inventors:
Thomas E. Barta - Evanston IL
Daniel P. Becker - Glenview IL
Terri L. Boehm - Ballwin MO
Gary A. De Crescenzo - St. Charles MO
Clara I. Villamil - Glenview IL
Joseph J. McDonald - Ballwin MO
John N. Freskos - Clayton MO
Daniel P. Getman - Chesterfield MO
Assignee:
G. D. Searle Company - St.Louis MO
International Classification:
A61K 31445
US Classification:
514330, 546192, 546225
Abstract:
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R and R are both hydrido or R and R together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

-Amino--Sulfonyl Hydroxamic Acid Compounds

US Patent:
6583299, Jun 24, 2003
Filed:
May 16, 2000
Appl. No.:
09/572019
Inventors:
Susan L Hockerman - Chicago IL
Daniel P. Becker - Glenview IL
Louis J Bedell - Mt. Prospect IL
Gary A DeCrescenzo - St. Charles MO
John N Freskos - Clayton MO
Daniel P Getman - Chesterfield MO
Robert M Heintz - Ballwin MO
Madeleine H Li - Vernon Hills MO
Brent V Mischke - Defiance MO
Clara I Villamil - Glenview IL
Thomas E Barta - Evanston IL
Assignee:
G.D. Searle Co. - Skokie IL
International Classification:
C07D31500
US Classification:
549419, 560312, 562800
Abstract:
A family of molecules is disclosed that inhibit matrix metalloprotease (MMP) activity, and particularly inhibit the activity of one or more of MMP-2, MMP-9, or MMP-13, while generally exhibiting little activity against MMP-1. A contemplated compound also exhibits little inhibition of the production of TNF. A contemplated compound is an -amino--sulfonyl carbocyclo, heterocyclo, aryl, or heteroaryl hydroxamic acid. Also disclosed are processes for preparing a contemplated compound and for treating a mammal having a condition associated with pathological matrix metalloprotease activity.

Use Of Sulfonyl Aryl Or Heteroaryl Hydroxamic Acids And Derivatives Thereof As Aggrecanase Inhibitors

US Patent:
6683078, Jan 27, 2004
Filed:
Jul 12, 2002
Appl. No.:
10/194897
Inventors:
Thomas E. Barta - Evanston IL
Elizabeth C. Arner - Wadsworth IL
Daniel Becker - Glenview IL
Terri L. Boehm - Ballwin MO
Gary A. DeCrescenzo - St. Charles MO
Joseph McDonald - Wildwood MO
Assignee:
Pharmacia Corporation - St. Louis MI
International Classification:
A61K 31535
US Classification:
5142315, 514277, 514278, 514316, 514318, 514320, 514321, 514326, 514336, 514357, 514365, 514374, 514375, 514378, 514397, 514398
Abstract:
This invention is directed to a process for inhibiting aggrecanase activity. The process comprises administering a therapeutically effective amount of a sulfonyl aromatic or heteroaromatic hydroxamic acid, a derivative thereof, or a pharmaceutically acceptable salt of the hydroxamic acid or derivative to a host animal. The compound generally corresponds in structure to the following formula: wherein W and the R groups are described in more detail in Applicants specification.

Aromatic Sulfone Hydroxamic Acids And Their Use As Protease Inhibitors

US Patent:
6683093, Jan 27, 2004
Filed:
Nov 21, 2001
Appl. No.:
09/989943
Inventors:
Thomas E. Barta - Evanston IL
Daniel P. Becker - Glenview IL
Louis J. Bedell - Mt. Prospect IL
Terri L. Boehm - Ballwin MO
Jeffery N. Carroll - Collinsville IL
Gary A. DeCrescenzo - St. Charles MO
Yvette M. Fobian - Labadie MO
John N. Freskos - Clayton MO
Daniel P. Getman - Chesterfield MO
Joseph J. McDonald - Ballwin MO
Madeleine H. Li - Vernon Hills IL
Susan L. Hockerman - Chicago IL
Carol Pearcy Howard - Fenton MO
Steve A. Kolodziej - Ballwin MO
Deborah A. Mischke - Defiance MO
Joseph G. Rico - Ballwin MO
Nathan W. Stehle - Ballwin MO
Michael B. Tollefson - OFallon MO
William F. Vernier - St. Louis MO
Clara I. Villamil - Glenview IL
Darren J. Kassab - Wildwood MO
Assignee:
Pharmacia Corporation - St. Louis MO
International Classification:
A61K 31445
US Classification:
514316, 514317, 514324, 514330, 544147, 546186, 546187, 546202
Abstract:
This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrecanase activity. This invention also is directed to a treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP activity and/or aggrecanase activity.

Sulfonyl Aryl Hydroxamates And Their Use As Matrix Metalloprotease Inhibitors

US Patent:
6696449, Feb 24, 2004
Filed:
Jul 19, 2001
Appl. No.:
09/909227
Inventors:
Thomas E. Barta - Evanston IL
Daniel P. Becker - Glenview IL
Louis J. Bedell - Prospect Heights IL
Gary A. DeCrescenzo - St. Charles MO
John N Freskos - Clayton MO
Daniel P. Getman - Chesterfield MO
Joseph J. McDonald - Wildwood MO
Brent V. Mischke - Defiance MO
Shashidhar N. Rao - Saint Louis MO
Clara I. Villamil - Glenview IL
Assignee:
Pharmacia Corporation - St. Louis MO
International Classification:
A61K 31496
US Classification:
51425503, 51425212, 51425218, 514309, 514312, 514331, 514469, 514575, 544360, 544383, 546141, 546153, 546233, 546234, 546331
Abstract:
This invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the compound corresponds in structure to one of the following formulas: wherein W , the R groups, and âAâRâEâY are described in more detail in Applicants specification. This invention also is directed to a process that comprises administering such a compound or pharmaceutically acceptable salt thereof to a host animal having a condition associated with MMP activity.

Aromatic Sulfone Hydroxamic Acid Metalloprotease Inhibitor

US Patent:
6750228, Jun 15, 2004
Filed:
May 12, 2000
Appl. No.:
09/570731
Inventors:
Thomas E Barta - Evanston IL
Daniel P Becker - Glenview IL
Louis J Bedell - Mt. Prospect IL
Terri L Boehm - Ballwin MO
Jeffrey N Carroll - Collinsville IL
Gary A DeCrescenzo - St. Charles MO
Yvette M Fobian - Wildwood MO
John N Freskos - Clayton MO
Daniel P Getman - Chesterfield MO
Joseph J McDonald - Ballwin MO
Madeleine H Li - Vernon Hills IL
Susan L Hockerman - Lincolnwood IL
Susan C Howard - Fenton MO
Steve A Kolodziej - Ballwin MO
Deborah A Mischke - Defiance MO
Joseph G Rico - Ballwin MO
Nathan W Stehle - Ballwin MO
Michael B Tollefson - Hainesville IL
William F Vernier - St. Louis MO
Clara I Villamil - Glenview IL
Assignee:
Pharmacia Corporation - St. Louis MO
International Classification:
A61K 31445
US Classification:
514316, 514318, 514328, 514330, 546189, 546193, 546220, 546225
Abstract:
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor. A contemplated compound corresponds in structure to formula B, below,.

Isbn (Books And Publications)

Datenschutz Im Krankenhaus

Author:
Thomas Barta
ISBN #:
3928083902

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.